, Gender Men, vol.7, pp.614-78

, 145) Notes: Comparison of survival (log-rank test) and years-of-life lost or costs per patient (Kruskal-Wallis test) were statistically significant for all characteristics. Abbreviations: HNSCC, head and neck squamous cell carcinoma, vol.2, p.221

. Gbd, Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global burden of disease study 2015, Lancet, vol.388, issue.16, pp.31678-31684, 2015.

, United States: Institute for Health Metrics and Evaluation (IHME), Global Burden of Disease Study 2015 (GBD 2015) Results. Seattle, 2015.

G. Gatta, L. Botta, and M. J. Sanchez, Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study, Eur J Cancer, vol.51, pp.2130-2143, 2015.

T. Y. Seiwert, B. Burtness, and R. Mehra, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol, vol.17, issue.7, pp.30066-30069, 2016.

R. L. Ferris, G. Blumenschein, and J. Fayette, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, vol.375, pp.1856-1867, 2016.

, Nivolumab for treating squamous cell carcinoma of the head and neck after platinumbased chemotherapy, 2017.

. Accessed, , 2017.

M. C. Ward, C. Shah, and D. J. Adelstein, Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer, Oral Oncol, vol.74, pp.49-55, 2017.

K. R. Tringale, K. T. Carroll, K. Zakeri, A. G. Sacco, L. Barnachea et al., Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, J Natl Cancer Inst, vol.110, issue.5, pp.479-485, 2018.

E. Wissinger, I. Griebsch, J. Lungershausen, T. Foster, and C. L. Pashos, The economic burden of head and neck cancer: a systematic literature review, PharmacoEconomics, vol.32, issue.9, pp.865-882, 2014.

M. Hashibe, P. Brennan, and S. C. Chuang, Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International head and neck cancer epidemiology consortium, Cancer Epidemiol Biomarkers Prev, vol.18, issue.2, pp.541-550, 2009.

J. Jegu, F. Binder-foucard, C. Borel, and M. Velten, Trends over three decades of the risk of second primary cancer among patients with head and neck cancer, Oral Oncol, vol.49, issue.1, pp.9-14, 2013.

C. S. Hollenbeak, A. N. Kulaylat, H. Mackley, W. Koch, E. W. Schaefer et al., Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers, JAMA Otolaryngol Head Neck Surg, vol.141, issue.7, pp.628-635, 2015.

V. Gregoire, J. L. Lefebvre, L. Licitra, E. Felip, and E. Group, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.21, issue.5, pp.184-186, 2010.

W. Nijdam, P. Levendag, I. Noever, C. U. Groot, and M. Agthoven, Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications, Radiat Oncol, vol.77, issue.1, pp.65-72, 2005.

, Agence Technique de l'Information sur l'Hospitalisation (ATIH)

À. Aide, utilisation Des Informations De Chaînage [How to Use De-Identified Patient Information

F. Lyon, Agence Technique de l'Information sur l'Hospitalisation, 2014.

Z. Uhry, A. Belot, and M. Colonna, National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: is this estimation correct?, Cancer Epidemiol, vol.37, issue.3, pp.270-277, 2013.

K. L. Schulman, K. Berenson, T. Shih, and Y. C. , A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working group, Value Health, vol.16, issue.4, pp.655-669, 2013.

M. B. Amin, S. Edge, and F. Greene, AJCC Cancer Staging Manual, 2017.

W. E. Barlow, Overview of methods to estimate the medical costs of cancer, Med Care, vol.47, issue.7, pp.33-36, 2009.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, issue.5, pp.373-383, 1987.

C. R. Boje, Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma -a systematic review, Radiat Oncol, vol.110, issue.1, pp.81-90, 2014.

H. Quan, V. Sundararajan, and P. Halfon, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Med Care, vol.43, issue.11, pp.1130-1139, 2005.

A. Bannay, C. Chaignot, and P. O. Blotiere, The best use of the Charlson comorbidity index with electronic health care database to predict mortality, Med Care, vol.54, issue.2, pp.188-194, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541

, Algorithme De Sélection Des Hospitalisations Liées À La Prise En Charge Du Cancer Dans Les Bases Nationales D'activité Hospitalière De Court Séjour « Algorithme Cancer » [Algorithm to select cancer-related hospitalizations in the French National Hospital Discharge

M. Distancier, MEsure des Trajets Inter-Communes/Carreaux)/ Calculs « Licencié », licence n°201602996, 2014.

A. Maladie, Rapport charges et produits pour l'année 2014. Assurance Maladie, 2013.

. Gbd, H. Dalys, and . Collaborators, Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global burden of disease study 2015, Lancet, vol.388, issue.16, p.31460, 2015.

M. B. Buntin and A. M. Zaslavsky, Too much ado about two-part models and transformation? Comparing methods of modeling medicare expenditures, J Health Econ, vol.23, issue.3, pp.525-542, 2004.

W. G. Manning and J. Mullahy, Estimating log models: to transform or not to transform?, J Health Econ, vol.20, issue.4, pp.461-494, 2001.

. Gbd, Risk factors collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global burden of disease study 2015, Lancet, vol.388, issue.16, pp.31679-31687, 2015.

E. P. Simard, L. A. Torre, and A. Jemal, International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site, Oral Oncol, vol.50, issue.5, pp.387-403, 2014.

G. Zigon, F. Berrino, and G. Gatta, Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study
URL : https://hal.archives-ouvertes.fr/hal-00555530

, Ann Oncol, vol.22, issue.1, pp.165-174, 2011.

A. V. Guizard, Z. Uhry, and D. De-raucourt, Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study, Eur J Cancer Prev, vol.26, pp.16-23, 2017.

J. L. St-guily, I. Borget, A. Vainchtock, V. Remy, and C. Takizawa, Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database, Head Neck Oncol, vol.2, p.22, 2010.

D. Greenberg, C. Earle, C. H. Fang, A. Eldar-lissai, and P. J. Neumann, When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology, J Natl Cancer Inst, vol.102, issue.2, pp.82-88, 2010.

P. J. Neumann, J. T. Cohen, and M. C. Weinstein, Updating cost-effectivenessthe curious resilience of the $50,000-per-QALY threshold, N Engl J Med, vol.371, issue.9, pp.796-797, 2014.

, DovePress ClinicoEconomics and Outcomes Research, vol.2019, p.11